2.0875
-0.1450
(-6.49%)
At close: January 10 at 5:26:08 PM GMT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
10,292.0000
10,292.0000
20,300.0000
57,866.0000
17,741.0000
Operating Income
-10,292.0000
-10,292.0000
-20,300.0000
-57,866.0000
-17,741.0000
Net Non Operating Interest Income Expense
635.0000
635.0000
207.0000
9.0000
9.0000
Pretax Income
-9,657.0000
-9,657.0000
-20,093.0000
-57,857.0000
-17,732.0000
Tax Provision
-1,249.0000
-1,249.0000
-2,448.0000
-9,194.0000
-3,816.0000
Net Income Common Stockholders
-8,408.0000
-8,408.0000
-17,645.0000
-48,663.0000
-13,916.0000
Diluted NI Available to Com Stockholders
-8,408.0000
-8,408.0000
-17,645.0000
-48,663.0000
-13,916.0000
Basic EPS
-0.05
-0.04
-0.09
-0.24
-0.09
Diluted EPS
-0.05
-0.04
-0.09
-0.24
-0.09
Basic Average Shares
201,360.0000
201,148.3250
201,426.9410
200,424.2170
147,103.5940
Diluted Average Shares
201,360.0000
201,148.3250
201,426.9410
200,424.2170
147,103.5940
Total Operating Income as Reported
-10,292.0000
-10,292.0000
-20,300.0000
-57,866.0000
-17,741.0000
Rent Expense Supplemental
168.0000
168.0000
168.0000
70.0000
--
Total Expenses
10,292.0000
10,292.0000
20,300.0000
57,866.0000
17,741.0000
Net Income from Continuing & Discontinued Operation
-8,408.0000
-8,408.0000
-17,645.0000
-48,663.0000
-13,916.0000
Normalized Income
-8,408.0000
-8,408.0000
-17,645.0000
-48,663.0000
-13,916.0000
Interest Income
635.0000
635.0000
207.0000
11.0000
19.0000
Interest Expense
--
--
--
2.0000
10.0000
Net Interest Income
635.0000
635.0000
207.0000
9.0000
9.0000
EBIT
-10,292.0000
-10,292.0000
-20,300.0000
-57,855.0000
-17,722.0000
EBITDA
-10,208.0000
-10,208.0000
-20,198.0000
-57,660.0000
-17,462.0000
Reconciled Depreciation
84.0000
84.0000
102.0000
195.0000
260.0000
Net Income from Continuing Operation Net Minority Interest
-8,408.0000
-8,408.0000
-17,645.0000
-48,663.0000
-13,916.0000
Normalized EBITDA
-10,208.0000
-10,208.0000
-20,198.0000
-57,660.0000
-17,462.0000
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0002
0.0002
12/31/2020 - 10/26/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
AVCT.L Avacta Group Plc
51.00
0.00%
SCLP.L Scancell Holdings plc
10.10
+3.59%
OPTI.L OptiBiotix Health Plc
17.50
0.00%
FARN.L Faron Pharmaceuticals Oy
200.00
0.00%
IMM.L ImmuPharma plc
3.5500
+1.43%
0EVI.IL Innate Pharma S.A.
1.8190
+2.19%
0QAJ.IL DBV Technologies S.A.
0.8715
-22.19%
0RQE.IL Idorsia Ltd
0.7725
-2.71%
PYC.L Physiomics Plc
0.8250
0.00%
AREC.L Arecor Therapeutics plc
58.50
-20.95%